IDYA News and Press, IDEAYA Biosciences Inc.

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE034, a Potential First-In-Class B7H3/PTK7 Bispecific TOP1 ADC PR Newswire Phase 1 dose escalation trial to determine safety, tolerability and PK of IDE034 Potential as a monotherapy and in combination with propr...

2026-02-23 18:25:01 ET IDEAYA Biosciences, Inc. (IDYA) Discusses Pipeline Progress and Upcoming Data Readout in Uveal Melanoma and ADC Programs February 23, 2026 12:00 PM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) D...

IDEAYA Biosciences Announces Appointment of Dr. Theodora (Theo) Ross, M.D., Ph.D., as Chief Development Officer PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 23, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today an...

2026-02-18 15:44:55 ET IDEAYA Biosciences, Inc. (IDYA) Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 1:00 PM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents at Citi's 2026 Virtual Oncology Lea...

2026-02-18 08:15:11 ET Wedbush analyst issues OUTPERFORM recommendation for IDYA on February 18, 2026 01:10PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $30.76 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...

2026-02-17 06:24:42 ET More on IDEAYA Biosciences IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow IDEAYA Bioscie...

IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update PR Newswire 130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uve...

Baxter International Inc. (BAX) is expected to report $0.53 for Q4 2025 Nova Ltd. (NVMI) is expected to report $1.94 for Q4 2025 West Pharmaceutical Services Inc. (WST) is expected to report $1.83 for Q4 2025 Universal Logistics Holdings Inc. (ULH) is expected to report $-0.05 for Q4 ...

IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 2, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and developme...

2026-01-13 01:45:57 ET IDEAYA Biosciences, Inc. (IDYA) 44th Annual J.P. Morgan Healthcare Conference January 12, 2026 6:45 PM EST... Read the full article on Seeking Alpha For further details see: IDEAYA Biosciences, Inc. (IDYA) Presents at 44th Annual J.P. Morgan Healthcare...